Patents by Inventor Sonya Zabludoff

Sonya Zabludoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS
    Publication number: 20100249112
    Abstract: A combination, comprising a checkpoint kinase (CHK) inhibitor, or a pharmaceutically acceptable salt thereof, and a poly (ADP-ribose)polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt thereof is described.
    Type: Application
    Filed: May 23, 2008
    Publication date: September 30, 2010
    Applicant: ASTRAZENECA R&D
    Inventors: Mark James O'Connor, Graeme Cameron Murray Smith, Sonya Zabludoff
  • COMBINATION OF CHECKPONIT KINASE (CHK) AND TELANGIECTASIA MUTATED (ATM) INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20100240645
    Abstract: A combination, comprising a checkpoint kinase (CHK) inhibitor, or a pharmaceutically acceptable salt thereof, and an ataxia telangiectasia mutated (ATM) inhibitor, or a pharmaceutically acceptable salt thereof is described.
    Type: Application
    Filed: May 23, 2008
    Publication date: September 23, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Graeme Cameron Murray Smith, Sonya Zabludoff
  • METHODS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES
    Publication number: 20100226917
    Abstract: The present invention discloses, in part, therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or B cell related tumors comprising the administration of a CHK1 inhibitor in combination with a B cell depleting antibody. The present invention further includes treating hematologic malignancies, including B cell lymphomas and leukemias, or B cell related tumors, which are resistant to cancer treatment comprising the administration of a CHK1 inhibitor.
    Type: Application
    Filed: April 24, 2008
    Publication date: September 9, 2010
    Applicant: AstraZeneca AB
    Inventors: Jennifer Brown, Sonya Zabludoff
  • Method for Determining Responsiveness to Chk1 Inhibitors
    Publication number: 20080145358
    Abstract: The invention is directed at a method for predicting a patient's responsiveness to a CHK1 inhibitor The method includes providing a sample from a test patient who is being treated with a DNA damaging agent; and determining for the presence of an activated CHK1 signal transduction pathway molecule, wherein the presence of an activated CHK1 signal transduction pathway molecule is indicative that a CHK1 inhibitor should be administered to the patient.
    Type: Application
    Filed: February 16, 2006
    Publication date: June 19, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Sonya Zabludoff, Louise Bergeron